Myriad Genetics (MYGN) Financials

$8.15 +0.10 (+1.24%)

Closing price 10/24/2025 04:00 PM Eastern

Extended Trading

$8.32 +0.17 (+2.13%)

As of 10/24/2025 07:57 PM Eastern

Annual Income Statements for Myriad Genetics

This table shows Myriad Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-112	-263	-127
Consolidated Net Income / (Loss)	-112	-263	-127
Net Income / (Loss) Continuing Operations	-112	-263	-127
Total Pre-Tax Income	-141	-262	-124
Total Operating Income	-141	-257	-124
Total Gross Profit	476	517	585
Total Revenue	678	753	838
Operating Revenue	678	753	838
Total Cost of Revenue	202	236	252
Operating Cost of Revenue	202	236	252
Total Operating Expenses	617	774	709
Selling, General & Admin Expense	248	284	276
Marketing Expense	267	289	284
Research & Development Expense	85	89	113
Other Operating Expenses / (Income)	0.00	113	-21
Impairment Charge	17	0.00	57
Total Other Income / (Expense), net	0.00	-4.80	0.00
Interest Expense	3.20	2.90	2.80
Interest & Investment Income	2.60	2.50	1.70
Other Income / (Expense), net	0.60	-4.40	1.10
Income Tax Expense	-29	1.10	3.80
Basic Earnings per Share	($1.39)	($3.18)	($1.41)
Weighted Average Basic Shares Outstanding	80.60M	82.80M	90.60M
Diluted Earnings per Share	($1.39)	($3.18)	($1.41)
Weighted Average Diluted Shares Outstanding	80.60M	82.80M	90.60M
Weighted Average Basic & Diluted Shares Outstanding	81.22M	89.87M	91.31M

This table shows Myriad Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-35	-42	-55	-116	-61	-31	-26	-37	-22	-43
Consolidated Net Income / (Loss)	-35	-42	-55	-116	-61	-31	-26	-37	-22	-43
Net Income / (Loss) Continuing Operations	-35	-42	-55	-116	-61	-31	-26	-37	-22	-43
Total Pre-Tax Income	-44	-52	-53	-116	-61	-32	-26	-37	-21	-39
Total Operating Income	-45	-52	-52	-114	-60	-31	-28	-37	-20	-39
Total Gross Profit	106	124	122	126	134	135	138	147	150	151
Total Revenue	156	178	181	184	192	197	202	212	213	211
Operating Revenue	156	178	181	184	192	197	202	212	213	211
Total Cost of Revenue	50	54	59	58	58	62	65	64	64	60
Operating Cost of Revenue	50	54	59	58	58	62	65	64	64	60
Total Operating Expenses	151	176	174	239	194	166	166	184	170	190
Selling, General & Admin Expense	131	-120	152	141	136	-145	141	145	139	-149
Research & Development Expense	21	23	23	21	24	21	25	27	29	33
Total Other Income / (Expense), net	0.80	0.10	-0.40	-2.40	-1.10	-0.90	2.00	-0.70	-1.20	-0.10
Interest Expense	0.80	0.90	0.50	0.50	1.00	0.90	0.50	0.80	0.80	0.70
Interest & Investment Income	1.10	1.00	0.70	0.50	0.60	0.70	0.60	0.40	0.40	0.30
Other Income / (Expense), net	0.50	-	-0.60	-2.40	-0.70	-0.70	1.90	-0.30	-0.80	0.30
Income Tax Expense	-9.10	-9.80	2.10	0.00	0.10	-1.10	0.10	-0.50	0.90	3.30
Basic Earnings per Share	($0.43)	($0.52)	($0.67)	($1.42)	($0.75)	($0.34)	($0.29)	($0.41)	($0.24)	($0.47)
Weighted Average Basic Shares Outstanding	80.70M	80.60M	81.30M	81.70M	81.90M	82.80M	89.90M	90.60M	90.90M	90.60M
Diluted Earnings per Share	($0.43)	($0.52)	($0.67)	($1.42)	($0.75)	($0.34)	($0.29)	($0.41)	($0.24)	($0.47)
Weighted Average Diluted Shares Outstanding	80.70M	80.60M	81.30M	81.70M	81.90M	82.80M	89.90M	90.60M	90.90M	90.60M
Weighted Average Basic & Diluted Shares Outstanding	81.03M	81.22M	81.56M	81.88M	82.20M	89.87M	90.51M	90.82M	91.04M	91.31M

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-192	75	-29
Net Cash From Operating Activities	-106	-111	-8.70
Net Cash From Continuing Operating Activities	-106	-111	-8.70
Net Income / (Loss) Continuing Operations	-112	-263	-127
Consolidated Net Income / (Loss)	-112	-263	-127
Depreciation Expense	53	62	61
Non-Cash Adjustments To Reconcile Net Income	85	65	111
Changes in Operating Assets and Liabilities, net	-132	14	-53
Net Cash From Investing Activities	-78	32	-12
Net Cash From Continuing Investing Activities	-78	32	-12
Purchase of Property, Plant & Equipment	-45	-73	-30
Acquisitions	-57	0.00	0.00
Purchase of Investments	-103	0.00	0.00
Divestitures	0.00	0.00	8.80
Sale and/or Maturity of Investments	128	105	9.00
Net Cash From Financing Activities	-8.00	153	-7.40
Net Cash From Continuing Financing Activities	-8.00	153	-7.40
Repayment of Debt	-0.70	-42	-120
Issuance of Debt	0.00	80	120
Issuance of Common Equity	6.30	124	5.90
Other Financing Activities, net	-14	-9.00	-14
Effect of Exchange Rate Changes	-0.60	0.60	-1.00

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	4.50	-44	-3.30	50	-28	56	-35	-4.40	8.60	2.10
Net Cash From Operating Activities	-2.80	-7.30	-33	-0.90	-22	-55	-19	2.60	0.70	6.60
Net Cash From Continuing Operating Activities	-2.80	-7.30	-33	-0.90	-22	-55	-19	2.60	0.70	6.60
Net Income / (Loss) Continuing Operations	-35	-42	-55	-116	-61	-31	-26	-37	-22	-43
Consolidated Net Income / (Loss)	-35	-42	-55	-116	-61	-31	-26	-37	-22	-43
Depreciation Expense	13	14	19	13	14	15	16	15	16	15
Non-Cash Adjustments To Reconcile Net Income	21	27	24	19	15	8.00	10	28	15	58
Changes in Operating Assets and Liabilities, net	-1.70	-5.60	-22	83	11	-58	-19	-3.30	-8.20	-23
Net Cash From Investing Activities	11	-36	35	12	-2.50	-12	-7.10	-6.40	7.50	-5.90
Net Cash From Continuing Investing Activities	11	-36	35	12	-2.50	-12	-7.10	-6.40	7.50	-5.90
Purchase of Property, Plant & Equipment	-18	-15	-24	-19	-18	-14	-8.60	-8.90	-6.30	-5.90
Net Cash From Financing Activities	-3.60	-2.10	-4.90	38	-2.50	122	-8.80	2.40	-3.10	2.10
Net Cash From Continuing Financing Activities	-3.60	-2.10	-4.90	38	-2.50	122	-8.80	2.40	-3.10	2.10
Repayment of Debt	-0.70	-	0.00	-1.40	-0.20	-40	-60	-20	-20	-20
Issuance of Debt	-	-	0.00	40	-	40	60	20	20	20
Issuance of Common Equity	0.90	2.40	-	-	-	124	-	-	-	2.90
Other Financing Activities, net	-3.80	-4.50	-4.90	-0.20	-2.30	-1.60	-8.80	-0.60	-3.10	-1.30
Effect of Exchange Rate Changes	-0.50	0.70	0.20	0.30	-0.60	0.70	-0.80	-0.70	1.20	-0.70

This table presents Myriad Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	1,199	1,147	1,028
Total Current Assets	275	314	298
Cash & Equivalents	57	132	102
Short-Term Investments	58	8.80	0.00
Accounts Receivable	102	114	121
Inventories, net	20	22	28
Prepaid Expenses	20	19	31
Current Deferred & Refundable Income Taxes	18	17	16
Plant, Property, & Equipment, net	83	119	117
Total Noncurrent Assets	841	714	612
Goodwill	287	287	286
Intangible Assets	380	350	262
Other Noncurrent Operating Assets	119	77	64
Total Liabilities & Shareholders' Equity	1,199	1,147	1,028
Total Liabilities	313	363	327
Total Current Liabilities	137	156	164
Accounts Payable	29	26	32
Accrued Expenses	94	114	119
Other Current Liabilities	14	16	13
Total Noncurrent Liabilities	176	207	162
Long-Term Debt	0.00	39	40
Noncurrent Deferred & Payable Income Tax Liabilities	27	30	33
Other Noncurrent Operating Liabilities	149	139	90
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	886	783	701
Total Preferred & Common Equity	886	783	701
Total Common Equity	886	783	701
Common Stock	1,261	1,416	1,459
Retained Earnings	-366	-630	-757
Accumulated Other Comprehensive Income / (Loss)	-8.90	-3.70	-0.80

This table presents Myriad Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,212	1,169	1,187	1,149	1,111	1,085	1,081
Total Current Assets	352	262	294	265	290	292	293
Cash & Equivalents	111	54	103	76	97	92	100
Short-Term Investments	83	25	19	10	7.40	4.90	0.00
Accounts Receivable	102	119	112	115	118	118	126
Inventories, net	20	22	23	25	25	26	26
Prepaid Expenses	20	24	21	21	25	22	24
Current Deferred & Refundable Income Taxes	18	18	18	18	18	18	17
Plant, Property, & Equipment, net	68	96	112	121	119	116	115
Total Noncurrent Assets	792	811	781	763	702	677	673
Goodwill	237	287	287	287	287	286	286
Intangible Assets	371	369	359	357	341	320	313
Other Noncurrent Operating Assets	119	125	129	120	74	71	74
Total Liabilities & Shareholders' Equity	1,212	1,169	1,187	1,149	1,111	1,085	1,081
Total Liabilities	295	334	452	466	351	345	350
Total Current Liabilities	129	143	221	209	146	149	154
Accounts Payable	30	37	40	34	33	33	30
Accrued Expenses	85	92	164	158	99	98	111
Other Current Liabilities	14	15	17	18	14	13	14
Total Noncurrent Liabilities	166	191	231	256	204	196	195
Long-Term Debt	-	-	38	39	39	39	39
Noncurrent Deferred & Payable Income Tax Liabilities	38	33	33	32	31	31	31
Other Noncurrent Operating Liabilities	128	158	160	186	135	126	125
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	917	835	735	683	760	741	732
Total Preferred & Common Equity	917	835	735	683	760	741	732
Total Common Equity	917	835	735	683	760	741	732
Common Stock	1,252	1,264	1,278	1,287	1,420	1,437	1,446
Retained Earnings	-324	-421	-537	-598	-656	-692	-714
Accumulated Other Comprehensive Income / (Loss)	-11	-7.40	-5.40	-5.30	-4.20	-4.00	-0.10

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-1.77%	11.03%	11.21%
EBITDA Growth	-852.59%	-116.04%	67.55%
EBIT Growth	-173.44%	-87.00%	53.25%
NOPAT Growth	26.19%	-83.07%	52.02%
Net Income Growth	-311.76%	-135.09%	51.65%
EPS Growth	-297.14%	-128.78%	55.66%
Operating Cash Flow Growth	-671.51%	-4.33%	92.16%
Free Cash Flow Firm Growth	-205.97%	40.75%	69.66%
Invested Capital Growth	25.63%	-4.93%	-6.24%
Revenue Q/Q Growth	2.57%	2.56%	1.70%
EBITDA Q/Q Growth	-11.07%	14.81%	-12.92%
EBIT Q/Q Growth	-6.95%	7.13%	-5.79%
NOPAT Q/Q Growth	-6.92%	7.48%	-6.65%
Net Income Q/Q Growth	-44.89%	4.05%	-9.74%
EPS Q/Q Growth	-47.87%	5.36%	-10.16%
Operating Cash Flow Q/Q Growth	2.03%	-74.65%	87.57%
Free Cash Flow Firm Q/Q Growth	-25.68%	16.23%	62.20%
Invested Capital Q/Q Growth	8.93%	7.11%	-4.85%
Profitability Metrics	-	-	-
Gross Margin	70.22%	68.64%	69.89%
EBITDA Margin	-12.87%	-25.04%	-7.31%
Operating Margin	-20.73%	-34.17%	-14.74%
EBIT Margin	-20.64%	-34.76%	-14.61%
Profit (Net Income) Margin	-16.51%	-34.96%	-15.20%
Tax Burden Percent	79.66%	100.42%	103.08%
Interest Burden Percent	100.43%	100.15%	100.90%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-15.31%	-25.80%	-13.11%
ROIC Less NNEP Spread (ROIC-NNEP)	-10.52%	35.30%	36.35%
Return on Net Nonoperating Assets (RNNOA)	3.22%	-5.75%	-4.05%
Return on Equity (ROE)	-12.08%	-31.55%	-17.15%
Cash Return on Invested Capital (CROIC)	-38.03%	-20.74%	-6.66%
Operating Return on Assets (OROA)	-11.11%	-22.33%	-11.26%
Return on Assets (ROA)	-8.89%	-22.45%	-11.71%
Return on Common Equity (ROCE)	-12.08%	-31.55%	-17.15%
Return on Equity Simple (ROE_SIMPLE)	-12.64%	-33.62%	-18.16%
Net Operating Profit after Tax (NOPAT)	-98	-180	-86
NOPAT Margin	-14.51%	-23.92%	-10.32%
Net Nonoperating Expense Percent (NNEP)	-4.79%	-61.10%	-49.46%
Return On Investment Capital (ROIC_SIMPLE)	-11.11%	-21.93%	-11.67%
Cost of Revenue to Revenue	29.78%	31.36%	30.11%
SG&A Expenses to Revenue	36.54%	37.67%	32.94%
R&D to Revenue	12.59%	11.78%	13.54%
Operating Expenses to Revenue	90.95%	102.81%	84.63%
Earnings before Interest and Taxes (EBIT)	-140	-262	-122
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-87	-189	-61
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.33	2.01	1.78
Price to Tangible Book Value (P/TBV)	5.36	10.75	8.19
Price to Revenue (P/Rev)	1.73	2.09	1.49
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.41	2.16	1.86
Enterprise Value to Revenue (EV/Rev)	1.48	1.95	1.42
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.05	0.06
Long-Term Debt to Equity	0.00	0.05	0.06
Financial Leverage	-0.31	-0.16	-0.11
Leverage Ratio	1.36	1.41	1.46
Compound Leverage Factor	1.37	1.41	1.48
Debt to Total Capital	0.00%	4.69%	5.35%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	4.69%	5.35%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	95.31%	94.65%
Debt to EBITDA	0.00	-0.20	-0.65
Net Debt to EBITDA	0.00	0.54	1.03
Long-Term Debt to EBITDA	0.00	-0.20	-0.65
Debt to NOPAT	0.00	-0.21	-0.46
Net Debt to NOPAT	0.00	0.57	0.73
Long-Term Debt to NOPAT	0.00	-0.21	-0.46
Altman Z-Score	2.15	1.90	1.84
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.00	2.01	1.82
Quick Ratio	1.58	1.64	1.36
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-245	-145	-44
Operating Cash Flow to CapEx	-234.66%	-151.30%	-29.29%
Free Cash Flow to Firm to Interest Expense	-76.41	-49.96	-15.70
Operating Cash Flow to Interest Expense	-33.22	-38.24	-3.11
Operating Cash Flow Less CapEx to Interest Expense	-47.38	-63.52	-13.71
Efficiency Ratios	-	-	-
Asset Turnover	0.54	0.64	0.77
Accounts Receivable Turnover	7.03	6.98	7.11
Inventory Turnover	11.41	11.22	10.19
Fixed Asset Turnover	10.69	7.44	7.09
Accounts Payable Turnover	6.92	8.65	8.68
Days Sales Outstanding (DSO)	51.89	52.31	51.31
Days Inventory Outstanding (DIO)	31.98	32.53	35.82
Days Payable Outstanding (DPO)	52.76	42.19	42.04
Cash Conversion Cycle (CCC)	31.11	42.65	45.09
Capital & Investment Metrics	-	-	-
Invested Capital	716	681	638
Invested Capital Turnover	1.06	1.08	1.27
Increase / (Decrease) in Invested Capital	146	-35	-43
Enterprise Value (EV)	1,006	1,471	1,185
Market Capitalization	1,176	1,573	1,248
Book Value per Share	$10.93	$9.53	$7.70
Tangible Book Value per Share	$2.71	$1.78	$1.67
Total Capital	886	822	741
Total Debt	0.00	39	40
Total Long-Term Debt	0.00	39	40
Net Debt	-170	-102	-63
Capital Expenditures (CapEx)	45	73	30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	23	17	32
Debt-free Net Working Capital (DFNWC)	137	158	134
Net Working Capital (NWC)	137	158	134
Net Nonoperating Expense (NNE)	14	83	41
Net Nonoperating Obligations (NNO)	-170	-102	-63
Total Depreciation and Amortization (D&A)	53	73	61
Debt-free, Cash-free Net Working Capital to Revenue	3.32%	2.23%	3.76%
Debt-free Net Working Capital to Revenue	20.25%	20.94%	15.99%
Net Working Capital to Revenue	20.25%	20.94%	15.99%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.39)	($3.18)	($1.41)
Adjusted Weighted Average Basic Shares Outstanding	80.60M	82.80M	90.60M
Adjusted Diluted Earnings per Share	($1.39)	($3.18)	($1.41)
Adjusted Weighted Average Diluted Shares Outstanding	80.60M	82.80M	90.60M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	81.22M	89.87M	91.31M
Normalized Net Operating Profit after Tax (NOPAT)	-87	-180	-47
Normalized NOPAT Margin	-12.76%	-23.92%	-5.57%
Pre Tax Income Margin	-20.73%	-34.81%	-14.74%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-43.75	-90.28	-43.71
NOPAT to Interest Expense	-30.76	-62.13	-30.88
EBIT Less CapEx to Interest Expense	-57.91	-115.55	-54.32
NOPAT Less CapEx to Interest Expense	-44.91	-87.41	-41.48
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-6.52%	10.57%	9.88%	2.34%	22.70%	10.57%	11.59%	15.26%	11.15%	7.12%
EBITDA Growth	-157.19%	-29.19%	-165.08%	-2,041.67%	-48.73%	55.84%	69.16%	78.89%	88.87%	-41.18%
EBIT Growth	-209.34%	-21.11%	-106.25%	-555.93%	-36.63%	38.51%	50.76%	68.30%	65.79%	-20.87%
NOPAT Growth	36.22%	-21.11%	-103.91%	-538.76%	-33.56%	39.85%	46.55%	67.90%	66.72%	-24.52%
Net Income Growth	-242.68%	-456.58%	-166.83%	-723.40%	-74.64%	26.24%	52.47%	68.39%	63.95%	-36.22%
EPS Growth	-243.33%	-642.86%	-157.69%	-688.89%	-74.42%	34.62%	56.72%	71.13%	68.00%	-38.24%
Operating Cash Flow Growth	92.88%	23.16%	28.60%	98.19%	-689.29%	-649.32%	43.98%	388.89%	103.17%	112.07%
Free Cash Flow Firm Growth	-136.52%	-154.69%	-171.45%	8.84%	84.87%	107.29%	108.02%	10.13%	-142.72%	13.59%
Invested Capital Growth	18.47%	25.63%	18.86%	-2.71%	-3.32%	-4.93%	-4.37%	4.61%	5.54%	-6.24%
Revenue Q/Q Growth	-12.77%	13.68%	1.91%	1.27%	4.58%	2.45%	2.85%	4.60%	0.85%	-1.27%
EBITDA Q/Q Growth	-554.17%	-22.61%	13.25%	-207.78%	54.57%	63.60%	39.41%	-110.68%	76.04%	-361.54%
EBIT Q/Q Growth	-151.41%	-17.30%	-1.15%	-119.89%	47.63%	47.20%	19.00%	-41.54%	43.48%	-86.54%
NOPAT Q/Q Growth	-152.81%	-16.00%	0.00%	-117.82%	47.14%	47.75%	11.15%	-30.82%	45.21%	-95.50%
Net Income Q/Q Growth	-148.94%	-20.51%	-29.31%	-112.25%	47.20%	49.10%	16.67%	-41.15%	39.78%	-92.31%
EPS Q/Q Growth	-138.89%	-20.93%	-28.85%	-111.94%	47.18%	54.67%	14.71%	-41.38%	41.46%	-95.83%
Operating Cash Flow Q/Q Growth	94.37%	-160.71%	-354.79%	97.29%	-2,355.56%	-147.51%	66.00%	113.98%	-73.08%	842.86%
Free Cash Flow Firm Q/Q Growth	-98.34%	-36.30%	16.92%	59.41%	67.09%	165.71%	-8.63%	-554.81%	11.11%	130.75%
Invested Capital Q/Q Growth	-0.96%	8.93%	1.40%	-11.06%	-1.58%	7.11%	2.00%	-2.71%	-0.71%	-4.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.77%	69.69%	67.33%	68.50%	69.98%	68.67%	68.05%	69.55%	70.23%	71.65%
EBITDA Margin	-20.08%	-21.65%	-18.43%	-56.02%	-24.34%	-8.65%	-5.09%	-10.26%	-2.44%	-11.40%
Operating Margin	-28.77%	-29.36%	-28.81%	-61.96%	-31.32%	-15.97%	-13.80%	-17.26%	-9.38%	-18.57%
EBIT Margin	-28.45%	-29.36%	-29.14%	-63.27%	-31.68%	-16.33%	-12.86%	-17.40%	-9.75%	-18.42%
Profit (Net Income) Margin	-22.44%	-23.79%	-30.19%	-63.27%	-31.94%	-15.87%	-12.86%	-17.35%	-10.36%	-20.18%
Tax Burden Percent	79.41%	81.19%	103.99%	100.00%	100.16%	96.59%	100.39%	98.66%	104.25%	108.42%
Interest Burden Percent	99.33%	99.81%	99.62%	100.00%	100.66%	100.62%	99.62%	101.09%	101.92%	101.03%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-21.98%	-21.68%	-20.96%	-46.29%	-24.90%	-12.06%	-10.53%	-14.67%	-8.28%	-16.50%
ROIC Less NNEP Spread (ROIC-NNEP)	-20.91%	-19.65%	-12.85%	-26.72%	-12.38%	-5.28%	-3.12%	-0.22%	6.63%	1.81%
Return on Net Nonoperating Assets (RNNOA)	7.46%	6.02%	3.23%	5.92%	2.37%	0.86%	0.34%	0.02%	-0.51%	-0.20%
Return on Equity (ROE)	-14.51%	-15.66%	-17.73%	-40.37%	-22.53%	-11.20%	-10.19%	-14.65%	-8.78%	-16.71%
Cash Return on Invested Capital (CROIC)	-32.10%	-38.03%	-34.74%	-25.38%	-26.75%	-20.74%	-18.51%	-21.03%	-17.80%	-6.66%
Operating Return on Assets (OROA)	-14.77%	-15.81%	-16.70%	-36.89%	-19.71%	-10.49%	-8.73%	-12.29%	-7.20%	-14.20%
Return on Assets (ROA)	-11.65%	-12.81%	-17.30%	-36.89%	-19.87%	-10.19%	-8.73%	-12.25%	-7.65%	-15.55%
Return on Common Equity (ROCE)	-14.52%	-15.66%	-17.73%	-40.37%	-22.53%	-11.20%	-10.19%	-14.65%	-8.78%	-16.71%
Return on Equity Simple (ROE_SIMPLE)	-8.43%	0.00%	-17.50%	-33.76%	-40.15%	0.00%	-30.87%	-20.96%	-15.85%	0.00%
Net Operating Profit after Tax (NOPAT)	-32	-37	-37	-80	-42	-22	-20	-26	-14	-27
NOPAT Margin	-20.14%	-20.55%	-20.17%	-43.37%	-21.92%	-11.18%	-9.66%	-12.08%	-6.56%	-13.00%
Net Nonoperating Expense Percent (NNEP)	-1.07%	-2.03%	-8.10%	-19.58%	-12.53%	-6.78%	-7.41%	-14.45%	-14.90%	-18.32%
Return On Investment Capital (ROIC_SIMPLE)	-3.44%	-4.13%	-4.38%	-10.29%	-5.83%	-2.67%	-2.45%	-3.28%	-1.82%	-3.70%
Cost of Revenue to Revenue	32.23%	30.32%	32.67%	31.50%	30.02%	31.33%	31.95%	30.45%	29.77%	28.35%
SG&A Expenses to Revenue	83.44%	-67.66%	83.72%	76.68%	70.92%	-73.65%	69.54%	68.51%	65.21%	-70.61%
R&D to Revenue	13.11%	13.16%	12.42%	11.55%	12.51%	10.68%	12.31%	12.81%	13.36%	15.62%
Operating Expenses to Revenue	96.55%	99.04%	96.14%	130.46%	101.30%	84.64%	81.85%	86.81%	79.61%	90.22%
Earnings before Interest and Taxes (EBIT)	-45	-52	-53	-116	-61	-32	-26	-37	-21	-39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-31	-39	-33	-103	-47	-17	-10	-22	-5.20	-24
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.68	1.33	2.26	2.57	1.92	2.01	2.31	2.99	3.40	1.78
Price to Tangible Book Value (P/TBV)	4.97	5.36	10.56	21.19	32.67	10.75	13.27	16.44	18.72	8.19
Price to Revenue (P/Rev)	2.33	1.73	2.72	2.70	1.79	2.09	2.26	2.76	3.02	1.49
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.95	1.41	2.45	2.79	1.99	2.16	2.43	3.19	3.62	1.86
Enterprise Value to Revenue (EV/Rev)	1.93	1.48	2.56	2.58	1.72	1.95	2.18	2.69	2.95	1.42
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.05	0.06	0.05	0.05	0.05	0.05	0.06
Long-Term Debt to Equity	0.00	0.00	0.00	0.05	0.06	0.05	0.05	0.05	0.05	0.06
Financial Leverage	-0.36	-0.31	-0.25	-0.22	-0.19	-0.16	-0.11	-0.10	-0.08	-0.11
Leverage Ratio	1.35	1.36	1.36	1.42	1.48	1.41	1.43	1.54	1.58	1.46
Compound Leverage Factor	1.34	1.36	1.35	1.42	1.49	1.41	1.42	1.56	1.61	1.48
Debt to Total Capital	0.00%	0.00%	0.00%	4.96%	5.33%	4.69%	4.85%	4.98%	5.06%	5.35%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	4.96%	5.33%	4.69%	4.85%	4.98%	5.06%	5.35%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	95.04%	94.67%	95.31%	95.15%	95.02%	94.94%	94.65%
Debt to EBITDA	0.00	0.00	0.00	-0.19	-0.17	-0.20	-0.22	-0.41	-0.72	-0.65
Net Debt to EBITDA	0.00	0.00	0.00	0.43	0.22	0.54	0.37	0.61	1.12	1.03
Long-Term Debt to EBITDA	0.00	0.00	0.00	-0.19	-0.17	-0.20	-0.22	-0.41	-0.72	-0.65
Debt to NOPAT	0.00	0.00	0.00	-0.21	-0.20	-0.21	-0.24	-0.36	-0.48	-0.46
Net Debt to NOPAT	0.00	0.00	0.00	0.49	0.25	0.57	0.40	0.54	0.75	0.73
Long-Term Debt to NOPAT	0.00	0.00	0.00	-0.21	-0.20	-0.21	-0.24	-0.36	-0.48	-0.46
Altman Z-Score	3.40	2.39	3.45	2.22	1.49	2.56	2.95	3.75	4.20	2.11
Noncontrolling Interest Sharing Ratio	-0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.73	2.00	1.83	1.33	1.27	2.01	1.99	1.96	1.90	1.82
Quick Ratio	2.29	1.58	1.38	1.06	0.96	1.64	1.52	1.44	1.46	1.36
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-134	-183	-152	-62	-20	13	12	-55	-49	15
Operating Cash Flow to CapEx	-15.82%	-50.00%	-141.28%	-4.79%	-126.29%	-405.19%	-216.28%	29.21%	11.11%	111.86%
Free Cash Flow to Firm to Interest Expense	-167.50	-202.93	-303.48	-123.18	-20.27	14.80	24.34	-69.19	-61.50	21.61
Operating Cash Flow to Interest Expense	-3.50	-8.11	-66.40	-1.80	-22.10	-60.78	-37.20	3.25	0.88	9.43
Operating Cash Flow Less CapEx to Interest Expense	-25.63	-24.33	-113.40	-39.40	-39.60	-75.78	-54.40	-7.88	-7.00	1.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.52	0.54	0.57	0.58	0.62	0.64	0.68	0.71	0.74	0.77
Accounts Receivable Turnover	6.76	7.03	6.29	6.31	6.76	6.98	6.53	6.99	6.84	7.11
Inventory Turnover	10.15	11.41	11.40	11.68	10.22	11.22	10.41	10.21	9.91	10.19
Fixed Asset Turnover	11.93	10.69	9.78	8.48	7.80	7.44	7.21	7.03	6.98	7.09
Accounts Payable Turnover	8.56	6.92	6.70	7.20	7.20	8.65	6.94	6.79	8.00	8.68
Days Sales Outstanding (DSO)	54.03	51.89	58.00	57.84	54.02	52.31	55.91	52.21	53.38	51.31
Days Inventory Outstanding (DIO)	35.95	31.98	32.01	31.26	35.70	32.53	35.05	35.74	36.84	35.82
Days Payable Outstanding (DPO)	42.64	52.76	54.44	50.72	50.72	42.19	52.57	53.75	45.61	42.04
Cash Conversion Cycle (CCC)	47.34	31.11	35.58	38.38	39.01	42.65	38.39	34.20	44.62	45.09
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	657	716	726	646	636	681	694	676	671	638
Invested Capital Turnover	1.09	1.06	1.04	1.07	1.14	1.08	1.09	1.21	1.26	1.27
Increase / (Decrease) in Invested Capital	103	146	115	-18	-22	-35	-32	30	35	-43
Enterprise Value (EV)	1,279	1,006	1,778	1,801	1,266	1,471	1,687	2,155	2,427	1,185
Market Capitalization	1,539	1,176	1,887	1,890	1,313	1,573	1,752	2,214	2,488	1,248
Book Value per Share	$11.37	$10.93	$10.28	$9.01	$8.35	$9.53	$8.45	$8.18	$8.06	$7.70
Tangible Book Value per Share	$3.84	$2.71	$2.20	$1.09	$0.49	$1.78	$1.47	$1.49	$1.46	$1.67
Total Capital	917	886	835	774	722	822	799	779	771	741
Total Debt	0.00	0.00	0.00	38	39	39	39	39	39	40
Total Long-Term Debt	0.00	0.00	0.00	38	39	39	39	39	39	40
Net Debt	-259	-170	-109	-89	-48	-102	-66	-59	-61	-63
Capital Expenditures (CapEx)	18	15	24	19	18	14	8.60	8.90	6.30	5.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)	30	23	40	-48	-30	17	40	45	39	32
Debt-free Net Working Capital (DFNWC)	223	137	118	73	56	158	144	143	139	134
Net Working Capital (NWC)	223	137	118	73	56	158	144	143	139	134
Net Nonoperating Expense (NNE)	3.60	5.76	18	37	19	9.22	6.47	11	8.10	15
Net Nonoperating Obligations (NNO)	-259	-170	-109	-89	-48	-102	-66	-65	-61	-63
Total Depreciation and Amortization (D&A)	13	14	19	13	14	15	16	15	16	15
Debt-free, Cash-free Net Working Capital to Revenue	4.54%	3.32%	5.70%	-6.93%	-4.11%	2.23%	5.15%	5.66%	4.74%	3.76%
Debt-free Net Working Capital to Revenue	33.75%	20.25%	17.03%	10.47%	7.64%	20.94%	18.63%	17.79%	16.87%	15.99%
Net Working Capital to Revenue	33.75%	20.25%	17.03%	10.47%	7.64%	20.94%	18.63%	17.79%	16.87%	15.99%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.43)	($0.52)	($0.67)	($1.42)	($0.75)	($0.34)	($0.29)	($0.41)	($0.24)	($0.47)
Adjusted Weighted Average Basic Shares Outstanding	80.70M	80.60M	81.30M	81.70M	81.90M	82.80M	89.90M	90.60M	90.90M	90.60M
Adjusted Diluted Earnings per Share	($0.43)	($0.52)	($0.67)	($1.42)	($0.75)	($0.34)	($0.29)	($0.41)	($0.24)	($0.47)
Adjusted Weighted Average Diluted Shares Outstanding	80.70M	80.60M	81.30M	81.70M	81.90M	82.80M	89.90M	90.60M	90.90M	90.60M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	81.03M	81.22M	81.56M	81.88M	82.20M	89.87M	90.51M	90.82M	91.04M	91.31M
Normalized Net Operating Profit after Tax (NOPAT)	-32	-32	-37	-25	-18	-22	-20	-17	-12	-27
Normalized NOPAT Margin	-20.14%	-18.11%	-20.17%	-13.81%	-9.41%	-11.18%	-9.66%	-8.24%	-5.84%	-13.00%
Pre Tax Income Margin	-28.26%	-29.30%	-29.03%	-63.27%	-31.89%	-16.43%	-12.81%	-17.59%	-9.94%	-18.61%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-55.63	-58.00	-105.60	-232.20	-60.80	-35.67	-52.00	-46.00	-26.00	-55.43
NOPAT to Interest Expense	-39.38	-40.60	-73.08	-159.18	-42.07	-24.42	-39.06	-31.94	-17.50	-39.10
EBIT Less CapEx to Interest Expense	-77.75	-74.22	-152.60	-269.80	-78.30	-50.67	-69.20	-57.13	-33.88	-63.86
NOPAT Less CapEx to Interest Expense	-61.50	-56.82	-120.08	-196.78	-59.57	-39.42	-56.26	-43.06	-25.38	-47.53
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Myriad Genetics (NASDAQ:MYGN) has experienced several financial trends over the past four years up to Q4 2024. Here is a summary of the key trends observed in recent quarterly financial statements across its income statements, cash flow statements, and balance sheets.

Revenue Growth: Operating revenue has steadily increased from $156.4 million in Q3 2022 to $210.6 million by Q4 2024, showing gradual top-line growth.
Gross Profit Expansion: Corresponding with revenue growth, gross profit rose from $106.0 million in Q3 2022 to $150.9 million in Q4 2024, indicating improving operational efficiency.
Improved Cash Position: Cash & equivalents increased from $53.6 million in Q1 2023 to $99.9 million by Q3 2024, highlighting stronger liquidity over time.
Reduction in Operating Expenses: Total operating expenses decreased from $194.4 million in Q3 2023 to $190.0 million in Q4 2024, implying better cost control aligned with revenue gains.
Consistent Investment in R&D: Research & development expenses have remained robust, ranging between $20-33 million quarterly, supporting innovation and future product development.
Continued Net Losses: Despite operational improvements, Myriad has reported net losses each quarter, with a consolidated net loss of $42.5 million in Q4 2024, reflecting ongoing profitability challenges.
Stable Debt Levels: Long-term debt has remained around $38-39 million consistently from 2022 through 2024, indicating stable leverage but no significant deleveraging.
Equity Stability: Total shareholders’ equity stands around $683 million in 2023 and $731 million by Q3 2024, showing moderate equity growth but not dramatic changes.
Negative Operating Income: Operating income remains negative in all recent quarters, for example, -$39.1 million in Q4 2024, continuing to pressure overall profitability.
Recurring Cash Flow Challenges: Despite positive net cash from operations in recent quarters, the company had -$54.8 million in operating cash flow in Q4 2023 and other quarters with negative operating cash, indicating periodic cash generation issues.

Summary: Myriad Genetics has demonstrated steady revenue and gross profit growth, effective R&D investment, and improved liquidity over the past four years. However, the company continues to report net losses and negative operating income, showing ongoing challenges in achieving profitability. Stable debt levels and equity positions suggest moderate financial stability, but managing expenses and turning operational profitability remain key goals for Myriad going forward.

10/25/25 11:30 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Myriad Genetics' Financials

When does Myriad Genetics' fiscal year end?

According to the most recent income statement we have on file, Myriad Genetics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Myriad Genetics' net income changed over the last 2 years?

Myriad Genetics' net income appears to be on an upward trend, with a most recent value of -$127.30 million in 2024, rising from -$112 million in 2022. The previous period was -$263.30 million in 2023. View Myriad Genetics' forecast to see where analysts expect Myriad Genetics to go next.

What is Myriad Genetics' operating income?

Myriad Genetics' total operating income in 2024 was -$123.50 million, based on the following breakdown:

Total Gross Profit: $585.40 million
Total Operating Expenses: $708.90 million

How has Myriad Genetics' revenue changed over the last 2 years?

Over the last 2 years, Myriad Genetics' total revenue changed from $678.40 million in 2022 to $837.60 million in 2024, a change of 23.5%.

How much debt does Myriad Genetics have?

Myriad Genetics' total liabilities were at $326.50 million at the end of 2024, a 10.1% decrease from 2023, and a 4.3% increase since 2022.

How much cash does Myriad Genetics have?

In the past 2 years, Myriad Genetics' cash and equivalents has ranged from $56.90 million in 2022 to $132.10 million in 2023, and is currently $102.40 million as of their latest financial filing in 2024.

How has Myriad Genetics' book value per share changed over the last 2 years?

Over the last 2 years, Myriad Genetics' book value per share changed from 10.93 in 2022 to 7.70 in 2024, a change of -29.5%.

Related Companies

This page (NASDAQ:MYGN) was last updated on 10/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Myriad Genetics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Financials

Annual Income Statements for Myriad Genetics

Quarterly Income Statements for Myriad Genetics

Annual Cash Flow Statements for Myriad Genetics

Quarterly Cash Flow Statements for Myriad Genetics

Annual Balance Sheets for Myriad Genetics

Quarterly Balance Sheets for Myriad Genetics

Annual Metrics And Ratios for Myriad Genetics

Quarterly Metrics And Ratios for Myriad Genetics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Myriad Genetics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools